AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AbbVie is set to acquire Apogee Therapeutics in a deal valued at $10.9 billion. The acquisition is framed as a strategic effort to enhance the company's research and presence within the immunology sector.
Coverage from Fierce Biotech, The Wall Street Journal, CNBC, and the AbbVie News Center emphasizes the transaction's focus on bolstering the firm's growth in immunology. Reports highlight the inclusion of a specific eczema drug candidate as a primary component of the deal.
Future developments will depend on the finalization of the acquisition process. Coverage does not yet specify the anticipated closing date for the transaction or the specific regulatory hurdles that may remain.
Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 148d ago.
Quick answers
What is the total value of the acquisition?
The acquisition of Apogee Therapeutics by AbbVie is valued at $10.9 billion.
What is the strategic goal of the purchase?
AbbVie intends to deepen its immunology portfolio, specifically acquiring an eczema drug prospect.
Which organizations are involved?
The companies involved in this transaction are AbbVie and Apogee Therapeutics.
Coverage (7)
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs BioPharma Dive · 148d ago
- AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion Yahoo Finance · 148d ago
- AbbVie to acquire Apogee Therapeutics in $10.9B deal Yahoo Finance · 148d ago
- AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect Fierce Biotech · 148d ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 148d ago
- AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push CNBC · 148d ago
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio AbbVie News Center · 148d ago
Topics
Related trends
Nike hosts first investor day in 9 years as it tries to rightsize its business
Nike hosts its first investor day in nine years as the athletic giant works to rightsize its business amid ongoing turnaround efforts.
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Diamondback nears $5 billion deal to buy drilling portfolio from Double Eagle, FT says
Diamondback Energy agreed to buy Double Eagle subsidiaries for about 15.56 million shares and $2.15 billion cash, valuing the deal at roughly $5 billion, with closing expected December 21, 2026.
Gen Z judges colleagues who use AI, but paradoxically may see it as the key to their own promotion
New survey coverage reveals a stark generational paradox as younger workers harbor deep concerns over artificial intelligence while eyeing promotion pathways.
Disney Announces $3 Billion in Cost Cuts, Ends Streaming Profit Disclosures
Disney announces $3 billion in cost cuts and ends streaming profit disclosures